Clinical Trials Browser

Withdrawn × Interventional × Fulvestrant × Clear all

NCT03169738 2025-02-21

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03169777 2025-02-21

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Phase 1/2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Carcinoma, Transitional Cell

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05905341 2023-11-08

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Phase 1 Withdrawn

BreastGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Ovarian Neoplasms

NCT03803761 2023-09-25

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms

NCT04901299 2023-08-01

HER2-Signal

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT05191004 2023-07-11

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Phase 1/2 Withdrawn

Breast Neoplasms

NCT04316169 2022-12-23

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Phase 1 Withdrawn

BreastOther solid neoplasm

Solid Tumor

NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Phase 1 Withdrawn

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT03377101 2018-08-14

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Phase 2 Withdrawn

Estrogen Receptor Positive

NCT02140437 2015-12-29

Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC

Phase 2 Withdrawn

Breast Neoplasms

NCT01004419 2015-10-02

Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02115594 2014-10-08

ENCORE305

Phase 2 Withdrawn

Breast Neoplasms